7 Stocks That Could Pay You Again and Again

🧪 Schrödinger’s profit needs an Ajax footnote  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

September 18, 2026   |   Read online   7 Stocks That Could Pay You Again and Again One pays shareholders every month. Another owns cell towers with contracts designed to increase revenue over time. A third operates critical energy infrastructure that generates steady cash flow. They’re part of a new list of 7 high-yield dividend stocks built to potentially deliver income year after year. Seven stocks. Seven potential income streams. 👉 See All 7 Dividend Stocks >> (By clicking the links above, you agree to receive emails from TradingTips and their affiliates. You can opt out at any time. - Privacy Policy)   🧪 Schrödinger’s profit needs an Ajax footnote THE READ · Friday, September 18, 2026 A research milestone and an equity gain tell different stories inside the same quarterly result.   ⚡ FIRST 90 SECONDS Schrödinger’s August report included both an Ajax collaboration milestone and an investment gain associated with the acquisition. Thursday completed SDGR’s fifth green session. The structural references come from the earlier multi-day range and repeated $21.40 ceiling. Jeffry Turnmire explains Supercharged Tickers, securities that trade like regular stocks without an options expiration date. (Ad) By clicking the link above you agree to periodic updates from ProsperityPub and its partners (privacy policy)   Schrödinger reported a quarterly profit while its operations still lost $41.5 million. The bridge between those two facts sits below the operating line. In its August 5 second-quarter report, the company recorded $48.9 million of total other income, primarily from a gain associated with Lilly's acquisition of Ajax Therapeutics. Net income was $6.0 million. Reading only that final number would hide how much the quarter depended on the value realized from an investment. Ajax also contributed through a separate channel. A $10 million collaboration milestone helped lift drug-discovery revenue to $23.0 million. A milestone earned through a research relationship and a gain on an equity holding reach different places in the accounts. Both can reward successful science. Neither establishes the amount of revenue that repeats next quarter. The same report described a software agreement with Bristol Myers Squibb, giving us another business relationship whose future contribution needs to be judged on its own terms. The stock has supplied a much faster story. StocksToTrade's completed history shows five consecutive green sessions through Thursday, September 17, taking SDGR from $18.80 to $30.24, a 60.85% cumulative gain. Thursday alone rose 26.37% on 9.03 million shares. September 2 and September 14 highs both sit around $21.40, and the last three completed sessions closed above that earlier ceiling. These are dated price observations. I have no verified fresh Thursday announcement that explains the acceleration, so the August report stays labeled August.   📊 BY THE NUMBERS $41.5M Second-quarter operating loss in Schrödinger’s August 5 report, despite reported net income. 5.8% Ajax equity stake at December 31, 2025, disclosed in the May 5 report. +60.85% SDGR’s cumulative move across five green sessions ending Thursday, September 17.   The accounting separates the two ways Ajax contributed.   A profitable investment can matter without making quarterly operating revenue repeatable.   Thursday’s closing history also leaves three eligible streaks to compare.   🔥 THE STREAK BOARD Streaks alive into Thursday, September 17’s close. Ranked by consecutive green sessions, then cumulative gain. MNOV · D5 +98.28% over five sessions, volume rose each day to 7.41 million. SDGR · D5 +60.85% over five sessions, volume expanded over the run to 9.03 million. ARMG · D3 +21.94% over three sessions, volume finished at 1.30 million after holding near 650,000.   The ownership arithmetic The ownership history helps explain why Ajax appears in more than one financial line. Schrödinger's May 5 report disclosed a 5.8% equity stake as of December 31, 2025. It described Lilly's acquisition agreement at up to $2.3 billion, including later payments tied to clinical and regulatory milestones. That is a dated stake percentage beside a conditional transaction value. Multiplying them would produce a tempting headline number without establishing how much cash Schrödinger received. I would use the subsequently reported gain to understand the quarter already on the books. For future payments, the relevant evidence is whether the specified milestones are achieved and what the company then records. A successful investment can support the economics of a research platform while arriving irregularly. Treating every realization as a new quarterly baseline would make the business look smoother than its contractual payment schedule allows.   Sponsored by MarketBeat Ten stocks examined through the lens of institutional accumulation MarketBeat’s research examines ten stocks its analysts associate with institutional accumulation. The report looks beyond the most familiar technology names and explains the company-level arguments behind its selections. Readers can review the names and the analysis together, then judge how much weight to give the positioning evidence alongside each business’s prospects and their own research. Read the company research   For the structural price test, Monday through Wednesday established a range whose high was $24.39. Thursday closed above it. A further close above $24.39 would confirm continued acceptance beyond that multi-session range. A close below the repeated $21.40 ceiling would invalidate my broader hold-above-the-old-range thesis. The distance between those references leaves room for an unresolved retracement. I would keep that uncertainty visible instead of turning every pullback into a verdict on the science. The next financial report offers a different test: how much of the result comes from software, collaboration milestones and investment gains. I want that breakdown before carrying this quarter's profit into a forecast. It will show which part of the business supplied the improvement, and how much of that improvement has a plausible route to recurring.   ⏳ THE 48-HOUR CLOCK FRI SEP 18 · 10 AM ET August state employment and unemployment occupies this BLS calendar slot, with regional labor detail. FRI SEP 18 · STANDARD EXPIRATION Equity, index, ETF and ETN options have their September standard expiration date. Settlement conventions vary by contract. MON SEP 21 · 9:30 AM ET The next regular U.S. equity session opens after the weekend. StocksToTrade’s holiday calendar shows no closure.   How would you separate Schrödinger’s repeatable revenue from its research successes? Walk me through the line item you would start with. — Cal Torres, Markets Editor P.S. Nine public companies supply the power, cooling, and networking infrastructure examined in StockEarnings’ data-center report. (Ad) Paid advertisement. Not investment advice. Free report. Companies named are examples for educational purposes and are not recommendations. All investing involves risk, including the possible loss of principal. By clicking the link above, you agree to receive emails from StockEarnings and our affiliates. You can opt out at any time.   📎 HANDPICKED FOR YOU Sponsored Seven AI businesses beyond the familiar chipmakers MarketBeat’s research includes warehouse automation and the systems that help large retailers move their goods. The software behind complex drug-development and regulatory workflows Alexander Green examines an embedded platform used by major biopharma companies and its planned migration. Paid advertisement on behalf of The Oxford Club, 105 W. Monument Street, Baltimore, MD 21201. Track records described are the advertiser's own and prices are split adjusted. Past performance is not indicative of future results. All investing involves risk of loss including total loss of principal. Not investment advice. Tomorrow's calendar, sent before the open The scheduled prints and the overnight moves, in one short morning email. Free. (From Good Morning Alerts)       FOMO FINANCE A Guardian Financial Publishing title WHY YOU’RE RECEIVING THIS EMAIL You’re receiving this email because at some point, you opted in to receive updates, news, or information on a specific topic we’ve previously discussed or shared. Whether it was through a subscription, a form submission, or another form of communication, your information was shared willingly, and we respect your decision to connect with us. Thank you for taking the time to read this. This message is part of an ongoing conversation between us, and we want you to have full transparency about why you received it, how your information is handled, and what to expect from future emails. SUBSCRIPTION & DELIVERY Your subscription is confirmed and your delivery preferences are up to date. You are currently receiving content based on the schedule and frequency associated with your registration. If you need to adjust your delivery window, change your email frequency, or pause updates temporarily, reply to this message and our team will process your request within one business day. A confirmation of your original registration is available upon request. UNSUBSCRIBING OR MANAGING YOUR PREFERENCES Everyone’s inbox is different. If you ever find our emails no longer relevant, there’s no hard feelings — use the unsubscribe link at the bottom of this email and it takes effect on the first click. If you’d rather adjust what you receive than leave entirely, reply with the word PREFERENCES and our team will help you tailor your delivery. We don’t use tricks or gimmicks to keep you subscribed. Our priority is that these emails add value to your day, and if they don’t, we respect your decision to part ways. CONTACTING US Questions about your subscription or anything you read here? Reply to this email or write to contact@guardian.pub. Mail can be sent to Stable Financial Publishing, 1013 Centre Road Suite 403-D, Wilmington, DE 19805. We read every reply. CONTENT DISCLAIMER FOMO Finance is for informational and educational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Trading involves substantial risk of loss and is not suitable for everyone. Past performance does not guarantee future results. The reads, pivot levels, streaks and scored calls published here are observations about market behavior — they are not recommendations, and nothing in them should be taken as a suggestion to buy, sell, or size a position. You are responsible for your own research and decisions. If you spot an error in anything we publish, reply and tell us; we correct mistakes promptly. HOW WE MAKE MONEY FOMO Finance is free to read. We keep it that way by including paid advertisements and affiliate links in some emails. If you click a link or make a purchase, we may receive compensation from the advertiser at no cost to you. Sponsored placements never change our editorial views, and we only run offers we believe are relevant to traders and investors. Paid placements are labeled where they appear. PAYMENTS & FRAUD PROTECTION We will never ask you to provide payment card numbers, bank account details, or login credentials by email. Any message requesting this information should be considered fraudulent and reported to our team immediately. If you have a question about a purchase made through us, reply within 30 days of the transaction date and a member of our team will provide your records. REPORTING SUSPICIOUS EMAILS If you receive a message claiming to be from FOMO Finance or Guardian Financial Publishing that looks suspicious, do not click any links in it. Forward it to our support team so we can investigate and protect other readers. PRIVACY & DATA HANDLING We take your privacy seriously and we do not sell your personal information. This section describes how we collect, use, and protect it; full details are in the Privacy Policy linked below. What we collect. The information you give us at signup or later by reply — typically your email address, and sometimes your name or phone number. We also receive technical information when you open an email or visit one of our pages, including IP address, browser and device type, and operating system. Our emails contain tracking pixels and tagged links that tell us whether a message was opened and which links were clicked, which is how we measure what is worth sending. How we use it. To deliver the content you signed up for, respond to your inquiries, maintain your subscription records, and improve what we publish. Service providers. We use outside vendors to send email, host pages, and measure performance. These providers process data on our behalf, under contract, and only for the purposes described here. They are not permitted to use your information for their own purposes. Your rights. You can ask what personal information we hold about you, correct it, or request that we delete it. Email contact@guardian.pub with your request and the address you subscribed with. Depending on where you live, you may have additional statutory rights, including under California, Colorado, and Virginia privacy law. Children. This publication is intended for adults. We do not knowingly collect personal information from anyone under 13. If we learn that we have, we delete it promptly. Changes. We may update this privacy policy occasionally. Changes will be reflected on the linked page. ACCESSIBILITY AND COMMUNICATION If you have trouble accessing the unsubscribe page, managing preferences, or understanding why you’re receiving this email, reach out directly to our support team. We aim to respond within a reasonable time frame and address your concerns effectively. Our communication is designed to be as inclusive as possible, but we know there’s always room for improvement. If you have feedback on how we can make our emails more accessible or relevant, please don’t hesitate to share. LEGAL INFORMATION We comply with all applicable laws and regulations regarding email communication, including maintaining high standards for consent-based communication. Your trust matters, and we work to ensure every email you receive meets these requirements. If you need clarification on our compliance policies or legal obligations, please ask. A COMMITMENT TO NON-INTRUSIVE EMAILS We aim to create a non-intrusive communication experience. We won’t overwhelm your inbox with excessive messages, and we work to keep our content clear and concise. If we ever fail to meet these standards, we encourage you to let us know. Feedback, whether positive or constructive, is always appreciated. Your thoughts help us understand how we can do better. While we cannot promise every suggestion will be implemented, we take the time to review and consider your input. A FINAL NOTE Email is one of the many ways we stay connected, but we understand it isn’t perfect for everyone. If there’s another way you’d prefer to hear from us, let us know — social, a different cadence, another channel entirely — and we’re open to finding what works. Our goal is never to disrupt or clutter your inbox. Every email sent is intended to provide value, and we appreciate your time and attention. This footer was designed to ensure transparency, provide essential information, and give you full control over your communication preferences. We hope it meets your expectations, but if there’s anything you’d like to see improved, we’re always here to listen.   This email may contain paid advertisements and affiliate links. Guardian Financial Publishing may receive compensation if you click a link or make a purchase. FOMO Finance is a publication of Guardian Financial Publishing (D/B/A) Stable Financial Publishing Privacy Policy  ·  Terms  ·  Disclaimer   Update your email preferences or unsubscribe here © 2026 Stable Financial Publications 1013 Centre Road Suite 403-D Wilmington, DE 19805, United States Powered by beehiiv